Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abivax SA - American Depositary Shares (NQ:ABVX)

111.23 +0.25 (+0.23%)
Streaming Delayed Price Updated: 9:52 AM EST, Dec 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abivax SA - American Depositary Shares

< Previous 1 2 Next >
News headline image
2 Under-the-Radar Stocks That Have Soared This Year ↗
These companies are worth your attention. 
Via The Motley Fool
News headline image
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy? ↗
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters. 
Via The Motley Fool
News headline image
Hedge Fund Boosts Stake in Amylyx Stock to $63 Million — Should Investors Follow? ↗
Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down. 
Via The Motley Fool
News headline image
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets ↗
A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Outlook For Abivax ↗
 
Via Benzinga
News headline image
6 Healthcare Stocks With Strong Upward Momentum ↗
 
Via Benzinga
News headline image
This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead ↗
A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch ↗
This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Centessa Stock Has Surged 77% Over the Past Year — But a Top Biotech Fund Is Still Buying ↗
A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Sold $49 Million of Cidara Stock — Then Merck Announced a $9.2 Billion Takeover ↗
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks. 
Via The Motley Fool
News headline image
This Brinker International Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Tilray Brands Posts Upbeat Results, Joins Byrna Technologies, Delta Air Lines And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
AMD To Rally More Than 47%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Why Is Abivax Stock Trading Higher On Monday? ↗
Abivax said Phase 3 trials showed obefazimod improved clinical outcomes in ulcerative colitis, meeting key endpoints with no new safety concerns. 
Via Benzinga
News headline image
Top 1% Biotech Abivax Surges On 'Compelling' Results In A Highly Watched Disease ↗
The company is working on a treatment for a form of inflammatory bowel disease, a highly watched disease area. 
Via Investor's Business Daily
Topics Government
News headline image
RH Posts Downbeat Results, Joins Frequency Electronics, Tronox And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Market Movers: Robinhood, AppLovin Surge into S&P 500 Amidst Crucial Earnings Season
The financial markets are abuzz with significant corporate developments as several key companies navigate pivotal moments, ranging from prestigious S&P index inclusions to critical quarterly earnings... 
Via MarketMinute
Topics Artificial Intelligence ETFs Retirement
News headline image
This Stock Is Up by 800% This Year -- but Is It a Buy? ↗
This little-known biotech might still deliver strong returns. 
Via The Motley Fool
News headline image
Earnings Scheduled For August 11, 2025 ↗
 
Via Benzinga
News headline image
Intel, Absci, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Dow Surges Over 200 Points; AT&T Posts Upbeat Earnings ↗
 
Via Benzinga
Topics Stocks
News headline image
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results ↗
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Abivax Stock Skyrockets On Strong Data From Inflammatory Bowel Disorder Study ↗
Abivax shares jump as obefazimod meets key Phase 3 trial endpoints in ulcerative colitis with strong remission rates and a favorable safety profile. 
Via Benzinga
News headline image
Why Vicor Shares Are Trading Higher By 39%; Here Are 20 Stocks Moving Premarket ↗
Shares of Vicor Corporation (NASDAQ:VICR) rose sharply in pre-market trading after posting second-quarter results. 
Via Benzinga
News headline image
Small-Cap Abivax Spikes 400% On Positive Late-Stage Ulcerative Colitis Drug Trial Results — Retail Buzz Builds Around Blockbuster Potential ↗
The drug candidate demonstrated a placebo-adjusted remission rate of 19.3% in the first study and 13.4% in the second study. 
Via Stocktwits
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.